| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.gtbl.in | |
| Market Cap | 1,285.21 Cr. | |
| Enterprise Value(EV) | 1,275.88 Cr. | 2023-03 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 39.87 | Trailing Twelve Months Ending 2023-06 |
| Price-Earning Ratio (PE) | 22.19 | Trailing Twelve Months Ending 2023-06 |
| Industry PE | 37.43 | Trailing Twelve Months Ending 2023-06 |
| Book Value / Share | 114.85 | Trailing Twelve Months Ending 2023-06 |
| Price to Book Value | 7.70 | Calculated using Price: 884.60 |
| Dividend Yield | 0.61 | Period Ending 2023-03 |
| No. of Shares Subscribed | 1.45 Cr. | 14,528,702 Shares |
| FaceValue | 5 | |
| About Gujarat Themis Biosyn Ltd. | ||
| Gujarat Themis Biosyn Ltd, established in 1981, is a biotech and synthetic product manufacturing company, having plants at Vapi, Hyderabad, with group turnover of over $ 40 million. It has EDMFs, available and WHO approved plants.The company has world-wide exports to satisfied customers, having customised facility for all products.The company’s principal activity is to manufacture and distributes pharmaceuticals bulk drugs called rifampicin produced by fermentation process. The company's products include preparations of active pharmaceutical ingredient rifampicin and lovastatin. The company exports its products to Europe and the United States. | ||
| 1 Day |
|
+1.53% |
| 1 Week |
|
-1.18% |
| 1 Month |
|
+10.00% |
| 3 Month |
|
+10.90% |
| 6 Month |
|
+23.72% |
| 1 Year |
|
+37.04% |
| 2 Year |
|
+32.79% |
| 5 Year |
|
+2168.21% |
| 10 Year |
|
+6810.94% |
| 9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
| Return on Equity (%) | 302.71 | 72.63 | 38.06 | 41.85 | 77.99 | 53.82 | 50.35 | 45.92 | ||
| Return on Capital Employed (%) | 113.74 | 80.38 | 54.67 | 42.22 | 44.88 | 85.96 | 67.89 | 67.91 | 61.53 | |
| Return on Assets (%) | 29.88 | 31.50 | 24.25 | 18.45 | 24.07 | 45.62 | 35.65 | 37.08 | 35.81 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
| Shh. Funds | -5 | -1 | 4 | 8 | 12 | 19 | 42 | 70 | 103 | 149 | |
| Non Curr. Liab. | 6 | 6 | 2 | 1 | 0 | 1 | 5 | 2 | 2 | 2 | |
| Curr. Liab. | 15 | 10 | 9 | 12 | 8 | 13 | 24 | 26 | 32 | 36 | |
| Minority Int. | |||||||||||
| Equity & Liab. | 16 | 15 | 15 | 21 | 20 | 33 | 71 | 98 | 137 | 187 | |
| Non Curr. Assets | 13 | 11 | 11 | 13 | 13 | 25 | 35 | 25 | 44 | 105 | |
| Curr. Assets | 3 | 3 | 3 | 8 | 8 | 8 | 36 | 73 | 93 | 81 | |
| Misc. Exp. not W/O | |||||||||||
| Total Assets | 16 | 15 | 15 | 21 | 20 | 33 | 71 | 98 | 137 | 187 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-06 Rs. Cr. TTM |
| Net Sales | 31 | 33 | 36 | 39 | 41 | 85 | 91 | 115 | 149 | 154 | |
| Other Income | 0 | 0 | 0 | 0 | 2 | 2 | 3 | 4 | 6 | 6 | |
| Total Income | 32 | 33 | 36 | 39 | 43 | 87 | 94 | 119 | 155 | 159 | |
| Total Expenditure | -25 | -27 | -30 | -33 | -34 | -53 | -50 | -57 | -75 | -79 | |
| PBIDT | 6 | 6 | 6 | 6 | 10 | 34 | 44 | 62 | 80 | 81 | |
| Interest | 0 | 0 | 0 | 0 | 0 | -1 | -1 | -1 | 0 | 0 | |
| Depreciation | -1 | -1 | -1 | -1 | -1 | -1 | -2 | -2 | -3 | -3 | |
| Taxation | -1 | -1 | -2 | -8 | -11 | -15 | -20 | -20 | |||
| Exceptional Items | |||||||||||
| PAT | 5 | 5 | 4 | 4 | 6 | 24 | 30 | 44 | 58 | 58 | |
| Adjusted EPS | 3 | 3 | 3 | 3 | 4 | 16 | 21 | 30 | 40 | 40 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
| Cash Fr. Operatn. | 4 | 3 | 4 | 3 | 6 | 1 | 1 | 11 | 40 | 40 | |
| Cash Fr. Inv. | 0 | 0 | -1 | -3 | -1 | -6 | -3 | -2 | -30 | -20 | |
| Cash Fr. Finan. | -3 | -3 | -3 | 0 | -4 | 5 | 2 | -5 | -14 | -13 | |
| Net Change | 1 | -1 | 0 | 0 | 1 | 0 | 0 | 3 | -4 | 6 | |
| Cash & Cash Eqvt | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 4 | 0 | 6 |
|
Fri, 22 Sep 2023
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Please find enclosed our communication under Regulation 39(3) of the SEBI (LODR) Regulations 2015 |
|
Thu, 21 Sep 2023
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Pursuant to regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (the Listing Regulations) read with part A of Schedule III of the Listing Regulations we wish to inform that the management of the Company will meet with Analysts/Investors on Thursday 28th September 2023; the details of the same are given below:Sr. no. Date Name Venue1 28th September 2023 Perpetuity Ventures MumbaiNote: The schedule of the aforesaid meetings is subject to change. The changes may happen due to exigencies on the part of Fund / Broking House / Company.No Unpublished Price Sensitive Information (UPSI) will be discussed in the meetings/calls.Pursuant to regulation 46(2) of the Listing Regulations aforesaid information shall be disclosed on the website of the company viz. www.gtbl.in |
|
Thu, 21 Sep 2023
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Pursuant to regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (the Listing Regulations) read with part A of Schedule III of the Listing Regulations we wish to inform that the management of the Company will meet with Analysts/Investors on Wednesday 27th September 2023; the details of the same are given below:Sr. no. Date Name Venue1 27th September 2023 Motilal Oswal Mumbai Incred Capital |
| Mon, 25 Sep 2023 |
Closing Above Previous High
|
Close Within 52 Week High Zone
|
Close Above Last Month High
|
High Increase in 1 Month
|
High Increase in 3 Months
|
Equities
M.F.
Sectors
StockEdge Social